Biote Corp

Price remains in a medium- and long-term downtrend following an early-August support failure, and despite extreme oversold readings, the structural bias favors bearish execution. Selling on a rebound into the broken support zone or moving averages (around $1.47–$1.56) aligns with resistance rejection. Defer outright selling now and wait for a minor rally into key resistance to trim positions.

• ↑Product recall resolved; production and margins to normalize by H2 2026.
• ↑Insider buying: Exec chairman acquired ~131,950 shares for $202K.
• ↓Q2 2026 net loss $0.23/sh versus $0.03 profit expected.